WuXi Biologics has begun construction on a Biologics Manufacturing Center of excellence in the city of Shijiazhuang, a one hour train ride from Beijing.
 
The new Biologics Center will be equipped with 48,000L bioreactor capacity and will be built to meet cGMP standards of the U.S., EU and China. It will mark the eighth drug substance manufacturing facility of WuXi Biologics, which says it plans to have more than 220,000L total manufacturing capacity by 2021.
 
“We are pleased to break ground today and look forward to the operations of this new Biologics Center,” said said Dr. Chris Chen, chief executive officer, WuXi Biologics. “This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners, and ultimately to benefit patients worldwide.”